View Older Stories View More Recent Stories
-
Vertex Pharma (VRTX) call put ratio 1 call to 1.3 puts into quarter results
-
Vertex (VRTX) PT Lowered to $38 at BMO Capital
-
Vertex Pharma (VRTX) receives marketing authorization in Canada for Alyftrek
-
U.S. large biotech stocks Q2 earnings preview
-
Vertex Pharma (VRTX) Announces European Commission Approval of ALYFTREK
-
William Blair Reiterates Outperform Rating on Vertex (VRTX)
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $420 at RBC Capital
-
Vertex Pharma (VRTX) reveals new data on ALYFTREK
-
RBC Capital weighs in on Vertex (VRTX) following IgAN competitor data
-
FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
-
Stifel on Sionna Therapeutics (SION): 'both compounds are able to attain exposures well above the modeled PK threshold'
-
BofA Securities Reiterates Buy Rating on Vertex (VRTX)
-
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
-
UBS Reiterates Buy Rating on Vertex (VRTX) after positive doc call on Journavx uptake
-
Erste Group Downgrades Vertex (VRTX) to Hold, 'The ratio of receivables to sales is also at a very high level'
-
Scotiabank Reiterates Sector Perform Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Approves Additional $4B Buyback Program
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Bernstein on Vertex (VRTX): 'We'd Sit Tght' Following Yesterday's Stock Sell-Off
-
H.C. Wainwright Reiterates Buy Rating on Vertex (VRTX)
-
Wolfe Research Downgrades Vertex (VRTX) to Peerperform
-
Vertex (VRTX) PT Raised to $462 at Bernstein SocGen Group
-
Stifel Reiterates Hold Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Vertex (VRTX) PT Lowered to $442 at Scotiabank
-
Leerink Partners Downgrades Vertex (VRTX) to Market Perform 'on Lower Pain Projections'
-
After-hours movers: Palantir, Ford, Clorox and more
-
Vertex Pharma (VRTX) Misses Q1 EPS by 20c; raises guidance
-
Vertex Pharma (VRTX) call put ratio 1.2 calls to 1 put into quarter results
-
Vertex Pharma (VRTX) call put ratio 5.8 calls to 1 put into quarter results
-
UBS Reiterates Buy Rating on Vertex (VRTX)
-
Cantor Fitzgerald Reiterates Overweight Rating on Vertex (VRTX)
-
Cantor Fitzgerald Assumes Vertex (VRTX) at Overweight
-
BMO Capital on Vertex (VRTX): 'Growth Continues as We Look Ahead to 1Q Earnings'
-
Pharma stocks slide after Trump signals tariffs on sector
-
Vertex Pharma (VRTX) announces European Commission approval of KAFTRIO label expansion
-
Vertex (VRTX) PT Raised to $420 at RBC Capital; 'Alyftrek Could Be Off To a Good Start'
-
Canaccord Genuity Reiterates Hold Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Announces Program Updates for Type 1 Diabetes Portfolio
-
DA Davidson Reiterates Buy Rating on Vertex (VRTX)
-
Vertex Pharma (VRTX) Announces UK MHRA Approval of ALYFTREK
-
Vertex Pharma (VRTX) Receives CHMP Positive Opinion for Expanded Label for KAFTRIO in Combination With Ivacaftor
-
Vertex (VRTX) PT Raised to $408 at RBC Capital
-
DA Davidson Reiterates Buy Rating on Vertex (VRTX)
-
TD Cowen Reiterates Buy Rating on Vertex (VRTX): 'VRTX is a Top 2025 L.C. Biotech Pick'
-
Vertex (VRTX) PT Raised to $520 at Truist on 'Incrementally Positive Commercial Outlook'
-
Vertex (VRTX) PT Raised to $459 at Morgan Stanley
-
BMO Capital Expects '2 New Launches to Drive 2025 PnL' for Vertex (VRTX)
-
Vertex (VRTX) PT Raised to $450 at Scotiabank

